



Review Article

Current recommendations for the Japanese encephalitis vaccine

Hui-Lan Chen^a, Jia-Kan Chang^b, Ren-Bin Tang^{b,*}

^a Department of Pediatrics, Keelung Hospital, Ministry of Health and Welfare, Keelung, Taiwan, ROC

^b Division of Pediatrics, Cheng-Hsin General Hospital, Taipei, Taiwan, ROC

Received April 30, 2014; accepted December 26, 2014

Abstract

Japanese encephalitis (JE) is a mosquito-borne flavivirus infection and an important cause of encephalitis in most of Asia and parts of the western Pacific. Most people infected with the JE virus (JEV) are asymptomatic or seemingly suffer from a nonspecific, flu-like illness; in others, JE can cause illness ranging from fever and headache to severe encephalitis. Although it can cause significant morbidity and mortality, JE is a vaccine-preventable disease, and vaccination programs have proven most effective in preventing and diminishing the burden of disease. Such JE vaccines have been available for decades with four types of JE vaccines—live attenuated SA14-14-2 vaccine, inactivated mouse brain-derived vaccine (JE-MB), inactivated Vero cell culture vaccine (JE-VC), and live attenuated chimeric vaccine (IMOJEV)—and are currently used in most countries. In some Asian countries such as Japan, China, Taiwan, Korea, and Thailand, immunization programs have been conducted for children and so the ongoing incidence of JE has declined considerably in recent decades. Until quite recently, the primary JE vaccine in use internationally has been the JE-MB, which is now commonly replaced by cell culture-based vaccines.

Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.

Keywords: inactivated mouse brain-derived vaccine (JE-MB); inactivated Vero cell culture vaccine (JE-VC); Japanese encephalitis (JE); live attenuated chimeric vaccine (IMOJEV); live attenuated SA14-14-2 vaccine

1. Introduction

Japanese encephalitis (JE) is the most common vaccine-preventable cause of encephalitis in Asia. It is responsible for an estimated 67,900 JE cases annually, has a 20–30% fatality rate and leaves neurologic or psychiatric sequelae in 30–50% of survivors.¹ JE virus (JEV) is a single-stranded RNA virus that belongs to the genus *Flavivirus* and is transmitted to humans through the bite of an infected mosquito, primarily *Culex* species. Fortunately, it cannot spread directly from person to person. JEV is transmitted in an enzootic cycle between mosquitoes and vertebrate hosts, mainly pigs and wading birds. Overall, humans are incidental or dead-end

hosts in the JEV transmission cycle. Because immunization is the major contributing factor to the decrease of JE, the World Health Organization (WHO) recommends that the JE vaccine be incorporated into immunization programs in all areas where the disease is a public health problem.^{2,3}

2. Epidemiology

JE is the main cause of viral encephalitis in many Asian countries; it is endemic with seasonal distribution in parts of China, the Russian Federation's south-east, and South and South-East Asia. To date, there has been no local transmission of JEV detected in Africa, Europe, or the Americas. There are a reported 30,000–50,000 clinical cases of JEV annually, with an estimated mortality ranging from 10 to 15,000 deaths.^{4,5} It is more common in rural areas where regular rice cultivation and flood irrigation occurs. In some developed Asian countries, use of the JE vaccine has dramatically decreased cases of

Conflicts of interest: The authors declare that there are no conflicts of interest related to the subject matter or materials discussed in this article.

* Corresponding author. Dr. Ren-Bin Tang, Division of Pediatrics, Cheng-Hsin General Hospital, 45, Cheng Hsin Street, Taipei 112, Taiwan, ROC.

E-mail address: ch9406@chgh.org.tw (R.-B. Tang).

the disease found in children. However, JE is still seen in adults, particularly the elderly.⁶ In data derived from populations in Taiwan and Thailand, the incidence of JE was noted to be 1.8 to 2.5 per 100,000 among unvaccinated children during placebo-control JE vaccine trials, whereas unvaccinated children in trials in China had an incidence of 5.7 to 64 per 100,000.^{7–9}

According to the Taiwan Centers for Disease Control (Taiwan CDC), transmission of JE in Taiwan occurs mostly between the months of May and October, and annually peaks between June and July. Since Taiwan began routine use of the JE vaccination in 1968, the annual confirmed case number over the last decade has been between 20 and 40, including 0–2 deaths; the average age of patients in Taiwan with JE exceeds 20.¹⁰ Due to the loss of vaccine-derived immunity in Taiwan, declining JE antibody prevalence ranged from 49% in primary school to 38% in junior high school, 34% in junior college, and 29% in university students.¹¹ For people who travel in Asia, the risk for JE is very low but varies by season, activities, travel destination, and duration of stay. The overall incidence of JE is estimated to be < 1 case per 1 million among people who travel from non-endemic countries to Asia.^{2–4}

3. Clinical features

JE is primarily a disease that afflicts children but can occur among people of any age. People infected with JEV mainly are asymptomatic; infection is symptomatic in less than 1% of cases, and typically involves severe encephalitis. The incubation period of JE is 5–15 days,^{2,3} and its earliest symptoms are lethargy, fever, headache, abdominal pain, nausea, and vomiting. Prodromal symptoms can evolve over several days to 1 week, when characteristic mental changes, focal neurological deficits, movement disorders and generalized weakness may develop over the next few days, thereafter advancing to progressive confusion, delirium, and coma. A minority of patients develop signs of increased intracranial pressure, such as papilledema and hypertension. Additionally, movement disorder such as nonstereotypical flailing, ataxia, or tremor may be present initially. Like Parkinson's syndrome, choreoathetosis, rigidity, masked facies, and other extrapyramidal signs may manifest later in the illness. Furthermore, 85% of children and 10% of adult develop focal or generalized seizure and multiple seizure and status epilepticus associated with a poor outcome.¹²

Laboratory studies disclose moderate leukocytosis with a left shift, mild anemia and hyponatremia. Cerebrospinal fluid (CSF) findings include mild to moderate pleocytosis, lymphocyte predominance, slightly elevated protein, and a normal ratio of CSF to plasma glucose. Imaging studies with electroencephalogram have revealed a pattern of diffuse slow waves with periodic lateralized epileptiform discharges (PLEDS). Magnetic resonance imaging (MRI) exhibited diffuse white matter edema, and abnormal signals in the thalamus, basal ganglia, cerebellum, midbrain, pons, and spinal cord. Thalamic lesions are the most commonly described abnormality.¹²

4. Treatment

Currently, there is no specific antiviral treatment for JE. Therapy for JE consists of supportive care and management of complications. The optimum way to prevent JE is to avoid mosquito bites. It is well understood that JE is a vaccine-preventable disease with four types of vaccines now available for active immunization. Vaccination programs have been proven the most effective in preventing and diminishing the burden of disease. All travelers to countries where JE occurs are at risk for JEV exposure and should take precautions to avoid mosquito bites. Because the risk of JE varies based on destination, duration of stay, activities, and seasonal patterns of disease in the areas to be visited, JE vaccination is recommended for travelers who plan to spend a month or longer in endemic areas during the JEV transmission season.^{13,14}

5. Type of JE vaccines and schedule

The four available JE vaccines are registered worldwide and used in national immunization programs for different age groups. Each of the vaccines incorporates a different vaccination schedule and booster dose requirement: (1) inactivated Vero cell culture vaccine (JE-VC) (IXIARO); (2) inactivated mouse brain-derived vaccine (JE-MB) manufactured in countries other than Japan; (3) a cell-culture-derived (primary hamster kidney) live attenuated vaccine based on the SA 14-14-2 strain manufactured in China; and (4) a live attenuated chimeric vaccine based on the genes of yellow fever 17D backbone combined with Vero cell propagated SA 14-14-2 strain (IMOJEV). Vero cell culture-derived inactivated vaccine based on the Beijing-1 strain (JEBIK-V and ENCEVAC) are manufactured for local use in Japan. Until quite recently, the main JE vaccine used internationally has been the inactivated JE-MB, which is effective in persons ≥ 1 years and administered in early childhood in two primary doses, with four to six additional boosters at various intervals until 15 years of age.^{13–15} The Nakayama strain of JEV, isolated from the CSF of a patient in 1935 and maintained by continuous mouse brain passage, has been the principal strain used in JE-MB produced throughout Asia.¹⁶ However, the JE-MB vaccine is now commonly replaced by cell culture-based vaccines.^{13,14} A new JE vaccine containing Beijing-3 (P3) vaccine strain grown in primary hamster kidney (PHK) cells was developed in China in 1968. The two new generations of JE vaccines, IXIARO and IMOJEV, have recently been licensed for routine use by countries in Europe, America, and Asia.¹⁷ A further overview of these vaccines used against JE is provided in Table 1.

6. Recommendations for the use of JE vaccine

The WHO recommends that the JE vaccine be incorporated into immunization programs in all areas where there is a risk of JEV transmission. According to information derived from a survey of JE vaccine programs, 11 (46%) of the 24 countries with JEV transmission risk had a JE immunization program in

Download English Version:

<https://daneshyari.com/en/article/3476092>

Download Persian Version:

<https://daneshyari.com/article/3476092>

[Daneshyari.com](https://daneshyari.com)